Glutamatergic medications show potential in treating obsessive-compulsive disorders

A recent meta-analysis found that glutamatergic medications may effectively treat obsessive-compulsive and related disorders (OCRDs), particularly obsessive-compulsive disorder (OCD). The analysis included 27 trials and showed significant symptom improvement compared to control groups. The study highlighted that while standard treatments like SSRIs work for many, about 60% of OCD patients do not respond adequately. Glutamatergic medications, which affect brain signaling, could offer new options for these patients. This review differs from previous ones by examining a broader range of OCRDs and medications. It suggests further research is needed to explore the effects of these treatments on different patient groups and conditions.